Clinical study of Remoxiumab combined with chemotherapy in second-line treatment of advanced gastric cancer
Objective Objective To value of remoxiumab combined with chemotherapy in second-line treatment of advanced gastric cancer.Methods 80 patients with advanced gastric cancer admitted to Cancer Department of Ziyang First People's Hospital from May 2022 to May 2023 were randomly divided into two groups.The control group(40 cases)received paclitaxel chemotherapy,and the observation group(40 cases)received remoxiumab combined with paclitaxel.Efficacy,adverse reactions,survival time,serum tumor markers and quality of life were observed.Results The disease control rate(DCR)(85.00％vs 65.00％)and objective response rate(ORR)(45.00％vs 22.50％)of the observation group were higher than those of the control group(P＜0.05),the median progression-free survival(PFS)time was longer than that of the control group(6.1 months vs 4.0 months),and the median overall survival(OS)was longer than that of the control group(9.0 months vs 6.1 months)(P＜0.05).The levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and carbohydrate antigen 199(CA199)in serum of observation group after treatment were lower than those of control group(P＜0.05),and the score of core quality of Life questionnaire(QLQ-C30)was higher than that of control group(P＜0.05).Conclusion Remoxiumab combined with chemotherapy in second-line treatment of advanced gastric cancer can increase disease control rate,prolong survival,improve quality of life,and have controllable safety.
万方数据
维普
